- Home
- BPOP vs PRAX Comparison
BPOP vs PRAX Comparison
Compare BPOP & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BPOP | PRAX |
|---|---|---|
| Founded | 1893 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BPOP | PRAX |
|---|---|---|
| Price | $126.13 | $297.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $135.11 | ★ $397.85 |
| AVG Volume (30 Days) | 434.0K | ★ 569.5K |
| Earning Date | 01-27-2026 | 02-27-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ 53.22 | N/A |
| EPS | ★ 11.28 | N/A |
| Revenue | ★ $2,876,597,000.00 | $7,463,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.08 | $14,827.76 |
| P/E Ratio | $11.19 | ★ N/A |
| Revenue Growth | 10.30 | ★ 364.98 |
| 52 Week Low | $78.23 | $26.70 |
| 52 Week High | $131.10 | $317.72 |
Technical Indicators
Market Signals| Indicator | BPOP | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 62.24 |
| Support Level | $123.82 | $266.93 |
| Resistance Level | $131.10 | $305.21 |
| Average True Range (ATR) | 2.34 | 15.96 |
| MACD | -0.52 | -3.30 |
| Stochastic Oscillator | 24.69 | 61.49 |
Price Performance
Historical ComparisonAbout BPOP Popular Inc.
Popular Inc, based in Puerto Rico, is a financial holding company with four main subsidiaries: Banco Popular de Puerto Rico, a bank in Puerto Rico in terms of assets; Banco Popular North America, its banking operation in the continental United States; Evertec, a data processor; and Popular Financial Holdings, a diversified financial services company. The Corporation's reportable segments consist of Banco Popular de Puerto Rico and Popular U.S.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.